Item 1A. Risk Factors
As discussed immediately prior to Item 1 of Part I, “Business”
under “Cautionary Note Regarding Forward-Looking Statements,” our actual results could differ materially from those expressed
in our forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed
below. Additional risks and uncertainties not presently known to us, or that we currently deem immaterial, may also impair our business
operations. If any of the following risks occur, our business, financial condition, operating results, cash flows and the trading price
of our common stock could be materially adversely affected.
Risks Relating to our Business
The impacts of the coronavirus pandemic could adversely affect
our business, and other similar crises could result in similar or other harms.
The outbreak of the novel coronavirus (COVID-19) pandemic has resulted
in widespread travel and transportation restrictions and closures of commercial spaces, industrial facilities and other spaces and businesses
in and across the United States and the world, including in the locations we operate or target sales. As a result, our business has been
impacted and we could face continued or more adverse effects. In addition, our results and financial condition may be adversely affected
by federal or state legislation, or other similar laws, regulations, orders or other governmental or regulatory actions or best practices,
that would impose new restrictions on our ability to operate our business or customers to operate their businesses. For example, our sales
and technical field forces have been restricted from traveling or limited in travel, which adversely affects our ability to sell our products
and complete field studies. While we have implemented cautionary procedures at our manufacturing facility, there may be disruptions to
our ability to manufacture due to current and additional workplace controls. Our customers may be less inclined or unable to purchase
our products or continue product studies due to restrictions under which they may be operating. Those restrictions have been and are more
severe in some jurisdictions, such as California. If financial markets tighten, we may have more limited ability to raise necessary financing.
The COVID-19 pandemic is also placing a significant budgetary burden on federal, state and local governments, which may impede or delay
their ability to purchase our products. We source some of our critical raw materials from Asia, and the coronavirus has caused supply
chain disruptions, which could limit a timely supply of materials. Each of these could have negative effects on our business, results
of operations, financial condition and cash flows. Even if the coronavirus pandemic passes, another crisis with similar effects could
develop and harm our business, financial results and liquidity. The degree to which the COVID-19 pandemic may impact our results of operations
and financial condition is unknown at this time and will depend on future developments, including the ultimate severity and the duration
of the pandemic, and further actions that may be taken by governmental authorities or businesses or individuals on their own initiatives
in response to the pandemic.
Our success is dependent on the successful commercialization
of ContraPest.
The EPA granted registration approval for ContraPest effective August
2, 2016, and as of July 12, 2018, we have received registration for ContraPest in all 50 states and the District of Columbia. However,
we have not yet had significant sales of ContraPest, which is our only product to date that is available for commercialization and the
generation of revenue.
ContraPest and our other product candidates, if approved, may
not achieve adequate market acceptance necessary for commercial success.
Even following receipt of regulatory approval for ContraPest or future
regulatory approval of our other product candidates, such products may not gain market acceptance. Market acceptance of any of our product
candidates for which we receive approval depends on a number of factors, including the following:
● the efficacy and safety of such product candidates as demonstrated in trials;
● relative convenience and ease of use; and
● unfavorable publicity relating to the product.
9
If we cannot successfully commercialize our products, especially
ContraPest, we will not become profitable.
If any of our approved product candidates fail to achieve sufficient
market acceptance, we will not be able to generate significant revenues or become profitable. The commercial success of ContraPest will
depend on a number of factors, including the following:
● continued refinement of our pricing strategy;
● a continued acceptable safety profile of ContraPest.
Many of these factors are beyond our control. If we are unable to successfully
commercialize ContraPest, we may not be able to earn sufficient revenues or profits to continue our business.
We will require additional capital to fund our operations. Failure
to obtain this necessary capital if needed may force us to delay, limit, or terminate our product development efforts or other operations.
Commercialization of ContraPest and developing further product candidates,
including conducting experiments and field studies, obtaining and maintaining regulatory approval and commercializing any products approved
for sale, is a time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to continue and to
increase in connection with our ongoing activities, particularly as we advance our commercialization activities. We may expand our operations,
and as a result of many factors, some of which may be currently unknown to us, our expenses may be higher than expected. Securing additional
financing may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our product candidates, including ContraPest. In addition, we cannot guarantee that future financing will be available in sufficient amounts
or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be
required to take certain actions, including the following:
The occurrence of any of the events described above would have a material
adverse effect on our business, operating results and prospects and on our ability to develop our product candidates.
ContraPest is the first product we have marketed, and if we are
unable to establish and maintain an effective sales force and marketing and distribution infrastructures, or enter into and rely upon
acceptable third-party relationships, we may be unable to generate any revenue.
We continue to develop a functional infrastructure for the sales, marketing,
and distribution of our products and the cost of establishing and maintaining such an infrastructure may exceed the cost-effectiveness
of doing so. In order to market ContraPest and any other products that may be approved by the EPA and comparable foreign regulatory authorities,
we must continue to build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties
to perform these services for which we would incur substantial costs. If we are unable to establish and maintain adequate sales, marketing,
and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue
to become profitable. Without an effective internal commercial organization or the support of a third party to perform sales and marketing
functions, we may be unable to compete successfully.
10
Risks Regulations Have on Our Business
Regulatory approval processes of the EPA and comparable foreign
regulatory authorities are lengthy, time-consuming and unpredictable, and if we are ultimately unable to obtain regulatory approval for
our product candidates, our business may fail.
The EPA review process for a product with one or more new active ingredients
typically takes approximately two years to complete and approval is never guaranteed. In addition, we continue to seek approvals to expand
labels and use designations for ContraPest to broaden its market and usability. Our efforts could fail to receive marketing approval from
the EPA or, with respect to ContraPest or our product candidates, from a comparable foreign regulatory authority for many reasons, including
the following:
● disagreement over the design or implementation of our trials;
● failure to demonstrate a product candidate’s benefits outweigh its risks;
● disagreement over our interpretation of data;
● disagreement over whether to accept efficacy results from trials;
● the insufficiency of data collected from trials to obtain regulatory approval;
Any of these factors, some of which are beyond our control, could jeopardize
our ability to obtain regulatory approval for and successfully market any of our product candidates. Any such setback in our pursuit of
regulatory approval could have a material adverse effect on our business and prospects.
Even following receipt of any regulatory approval for ContraPest
and our other product candidates, we will continue to face extensive regulatory requirements and our products may face future development
and regulatory difficulties.
Even following receipt of any regulatory approval for ContraPest or
our product candidates, our products will be subject to ongoing requirements by the EPA and comparable state and foreign regulatory authorities
governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety surveillance, import,
export, advertising, promotion, recordkeeping and reporting of safety and other post-market information.
The safety profile of any product will continue to be closely monitored
by the EPA and comparable foreign regulatory authorities after approval. In addition, we may be required, from time to time, to provide
further testing results and certifications to the EPA and state regulatory agencies for ContraPest.
For instance, we have found it challenging to produce applicable stability
test results for certain of our active ingredients, due in part to the small quantities used in the final product and continue to work
with the EPA to develop appropriate biological or chemical measurements of product stability. Because our data continue to demonstrate
the long-term efficacy of ContraPest, we believe that the testing is a matter we will resolve.
If the EPA or comparable foreign regulatory authorities become aware
of new information after approval of ContraPest or any other product candidate, or we are unable to adequately complete required testing
and certification requirements, a number of potentially significant negative consequences could result, including the following:
● we may be forced to suspend marketing of such product;
● we could be sued and held liable for harm caused;
● we may be subject to litigation or product liability claims; and
● our reputation may suffer.
11
Any of these events could prevent us from achieving or maintaining
market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and
prospects.
Moreover, existing government regulations may change, and additional
government regulations may be enacted that could prevent, limit or delay regulatory approval of ContraPest or any other product candidates.
If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not
able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and/or be subject to different marketing
requirements or fines or enhanced government oversight and reporting obligations, which would adversely affect our business, prospects,
and ability to achieve or sustain profitability.
Our future success is also dependent on regulatory approval and
commercialization of our other product candidates.
We are actively working on a semi-solid product as well as an alternative
dispenser. We also plan to continue work on a product to control fertility in mice. We cannot commercialize our product candidates in
the United States without first obtaining regulatory approval for each product and each use pattern from the EPA or, if applicable, the
Food and Drug Administration, or FDA, and from any related applicable state authorities. Before obtaining regulatory approvals for the
commercial sale of any product candidate for a target indication, the law requires that applicants demonstrate through laboratory and
field studies and related data showing that the product candidate will perform its intended function without causing unreasonable adverse
effects on the environment. The EPA or a comparable foreign regulatory authority may require more information, including additional data
to support approval that may delay or prevent approval.
Even following receipt of any regulatory approval for ContraPest
and our other product candidates, we will continue to be subject to regulation of our manufacturing processes and advertising practices.
As a manufacturer of pest control products, we are subject to continual
government oversight and periodic inspections by the EPA and other regulatory authorities. If we or a regulatory agency discover problems
with a facility where our products are manufactured, a regulatory agency may impose restrictions on the manufacturing facility, including
requiring recall or withdrawal of the product from the market or suspension of manufacturing until certain procedural requirements have
been met. The occurrence of any such event or penalty could limit our ability to market ContraPest or any other product candidates and
generate revenue.
In addition, the EPA strictly regulates the advertising and promotion
of pest control products, and these pest control products may only be marketed or promoted for their EPA approved uses, consistent with
the product’s approved labeling. Advertising and promotion of any product candidate that obtains approval in the U.S. will be heavily
scrutinized by the EPA, other applicable state regulatory agencies and the public. Violations, including promotion of our products for
unapproved or off-label uses, are subject to enforcement actions, inquiries and investigations, and civil, criminal and/or administrative
sanctions imposed by the EPA.
Failure to obtain regulatory approval in foreign jurisdictions
would prevent ContraPest or any other product candidates from being marketed in those jurisdictions.
To market and sell our products globally, we must obtain separate marketing
approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve
additional testing. Obtaining foreign regulatory approvals and maintaining compliance with foreign regulatory requirements could result
in significant delays, difficulties, and cost for us and could delay or prevent the introduction of our products in certain countries.
Approval by the EPA does not ensure approval by regulatory authorities in other countries or jurisdictions, but EPA approval may influence
decisions by the foreign regulatory authority. If we are unable to obtain approval of ContraPest or for any of our other product candidates
by regulatory authorities in the world market, the commercial prospects of that product candidate may be significantly diminished and
our business prospects could decline.
Risks Related to our Operations and Supply Chain
We depend on key personnel to operate our business. If we are
unable to retain, attract and integrate qualified personnel, our ability to develop and successfully grow our business could be harmed.
We believe that our success is highly dependent on our ability to attract
and retain highly skilled and experienced sales, research and development, and other personnel. If one or more of our executive officers
or key employees terminates employment or becomes disabled or experiences long-term illness, we may not be able to replace their expertise,
fully integrate new personnel or replicate the prior working relationships, and the loss of their services might significantly delay or
prevent the achievement of our research and development and business objectives. Qualified individuals with the breadth of skills and
experience in our industry that we require are in high demand, and we may incur significant costs to attract them. Many of the other companies
that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a more established
history in the industry. They also may provide more diverse opportunities and better chances for career advancement. Our failure to attract
and/or retain key personnel could impede the achievement of our research and development and commercialization objectives.
12
We have internal manufacturing capabilities to meet our current
and near term forecasted demand for ContraPest, however, we must develop additional manufacturing capability or rely upon third parties
to manufacture our products to meet future demand and our single location manufacturing operations could be disrupted.
Our existing internal manufacturing platform is adequate for meeting
our current and near term forecasted demand for ContraPest. We may be required to spend significant time and resources to expand these
manufacturing facilities to fully meet future demand. If we are unable to develop full-scale manufacturing capabilities, we may not be
able to meet demand of our products without relying on third party manufacturers, which could adversely affect our operations or financial
condition.
In addition, if our manufacturing operations fail or are disrupted
for any reason, including because of labor, disasters, and/or equipment malfunctions, among others, our ability to timely produce ContraPest
may be adversely affected, which would harm our sales and reputation. We only operate in a single location, which means we do not
have back-up facilities to produce our products during a time when our manufacturing facility becomes unavailable.
We will need to expand our operations and grow the size of our
organization, and we may experience difficulties in managing this growth.
As of December 31, 2021, we had 26 full-time employees. As our development
and commercialization plans and strategies develop, we will need additional managerial, operational, sales, marketing, scientific and
financial headcount and other resources. Our management, personnel, and systems currently in place may not be adequate to support this
future growth. Future growth would impose significant added responsibilities on members of management, including the following:
● expanding our facilities.
Our failure to accomplish any of these tasks could prevent us from
successfully growing our business.
Business or supply chain disruptions could seriously harm our
future revenues and financial condition and increase our costs and expenses, particularly because we have limited suppliers and a critical
ingredient is sourced from China.
Our operations could be subject to a variety of potential business
disruptions, including power shortages, telecommunications failures, water shortages, floods, fires, earthquakes, extreme weather conditions,
medical epidemics and other natural or manmade disasters or other interruptions, for which we are predominantly self-insured. We do not
carry insurance for all categories of risk that our business may encounter. The occurrence of any of these business disruptions could
seriously harm our operations and financial condition and increase our costs and expenses. Moreover, we rely on third parties to supply
various ingredients and other items which are critical for producing our product candidates.
We currently use one supplier for each of our two active ingredients,
triptolide and VCD. Our ability to produce our product candidates would be disrupted if the operations of these suppliers are affected
by a man made or natural disaster or other business interruption. Because triptolide is sourced from China and other Asian countries,
we have a greater risk of supply interruption, including as a result of tariff and trade disputes, or disruptive events like the outbreak
of COVID-19. The ultimate impact on our operations from any business interruption impacting us or any of our significant suppliers is
unknown, but our operations and financial condition would likely suffer adverse consequences. Further, any significant uninsured liability
may require us to pay substantial amounts, which would adversely affect our business, results of operations, financial condition and cash
flows from future prospects.
We are dependent on triptolide, a key ingredient for ContraPest,
which has limited sources and must be in a very refined condition.
If we are unable to develop additional sources of or alternatives to
triptolide, a key ingredient for ContraPest, our long-term ability to produce ContraPest at a cost effective price could be in jeopardy.
If market demand for triptolide causes the price to increase beyond our ability to market at a competitive price or causes the quality
of the refined ingredient to be less than needed for our production, our ability to commercialize ContraPest could be limited or delayed,
which would adversely affect our business, results of operations and financial condition.
13
A variety of risks associated with marketing our product candidates
internationally could materially adversely affect our business.
We may seek regulatory approval of our product candidates outside of
the U.S. and, in that case, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain
the necessary approvals, including the following:
● differing regulatory requirements in foreign countries;
● foreign taxes, including withholding of payroll taxes;
● difficulties staffing and managing foreign operations;
These and other risks associated with our international operations
may materially adversely affect our ability to attain or maintain profitable operations.
14
Risks Relating to Protections of our Intellectual Property and Legal
Actions
If we fail to obtain or protect intellectual property rights,
our competitive position could be harmed.
We depend on our ability to protect our proprietary technology. We
rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing, and other agreements with employees and third
parties, all of which offer only limited protection. Our commercial success will depend in part on our ability to obtain and maintain
intellectual property protection in the United States and other countries with respect to our proprietary technology and products. Where
we deem appropriate, we seek to protect our proprietary position by filing patent applications in the United States and internationally
related to our novel technologies and products that are important to our business. However, our financial resources constrain us from
seeking protection in every instance, so we may rationalize and selectively pursue expensive patent protection. Patent positions can be
highly uncertain, involve complex legal and factual questions and be the subject of litigation. As a result, the issuance, scope, validity,
enforceability and commercial value of our patents, including those patent rights licensed to us by third parties, are highly uncertain.
The steps we have taken to protect our proprietary rights may not be
adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside
and outside the United States. The rights already granted under any of our currently issued patents and those that may be granted under
future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. If we are unable to
obtain and maintain protection for our technology and products, or if the scope of the protection obtained is not sufficient, our competitors
could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our
technology and products may be adversely affected.
With respect to patent rights, we do not know whether any of our pending
patent applications for any of our technologies or products will result in the issuance of patents that protect such technologies or products,
or if our licensed patent will effectively prevent others from commercializing competitive technologies and products. Our pending patent
applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent
issues from such applications. Further, the examination process may require us to narrow the claims for our pending patent applications,
which may limit the scope of patent protection that may be obtained if these applications issue. Because the issuance of a patent is not
conclusive as to its inventorship, scope, validity or enforceability, issued patents that we own or have licensed from third parties may
be challenged in the courts or patent offices in the U.S. and internationally. Such challenges may result in the loss of patent protection,
the narrowing of claims in such patents, or the invalidity or unenforceability of such patents, which could limit our ability to stop
others from using or commercializing similar or identical technology and products or limit the duration of the patent protection for our
technology and products. Protecting against the unauthorized use of our patented technology, trademarks and other intellectual property
rights, is expensive, difficult, and in some cases, may not be possible. In some cases, it may be difficult or impossible to detect third
party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any
such infringement may be even more difficult.
Intellectual property rights do not necessarily address all potential
threats to any competitive advantage we may have.
The degree of future protection afforded by our intellectual property
rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to
maintain our competitive advantage. The following examples are illustrative:
● the patents of others may have an adverse effect on our business.
15
Our technology may be found to infringe third party intellectual
property rights.
Third parties may in the future assert claims or initiate litigation
related to their patent, copyright, trademark and other intellectual property rights in technology that is important to us. The asserted
claims and/or litigation could include claims against us, our licensors, or our suppliers alleging infringement of intellectual property
rights with respect to our product candidates or components of those products. Regardless of the merit of the claims, they could be time
consuming, resulting in costly litigation and diversion of technical and management personnel, or require us to develop non-infringing
technology or enter into license agreements. We cannot assure you that licenses will be available on acceptable terms, if at all. Furthermore,
because of the potential for significant damage awards, which are not necessarily predictable, it is not unusual to find even arguably
unmeritorious claims resulting in large settlements. If any infringement or other intellectual property claim made against us by any third
party is successful, or if we fail to develop non-infringing technology or license the proprietary rights on commercially reasonable terms
and conditions, our business, operating results and financial condition could be materially adversely affected.
If our product candidates, methods, processes and other technologies
infringe the proprietary rights of other parties, we could incur substantial costs and we may have to take certain actions, including
the following:
● redesign our product candidates or processes to avoid infringement;
● stop using the subject matter claimed to be held by others;
● pay damages; or
We may need to license intellectual property from third parties,
and such licenses may not be available or may not be available on commercially reasonable terms.
A third party may hold intellectual property, including patent rights
that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary
technology of a third party to manufacture or otherwise commercialize our own technology or products, in which case we would be required
to obtain a license from such third party. Licensing such intellectual property may not be available or may not be available on commercially
reasonable terms, which could have a material adverse effect on our business and financial condition.
We may be subject to legal proceedings in the ordinary course
of our business that could result in significant harm to our business, financial condition and operating results.
We could be subject to legal proceedings and claims from time to time
in the ordinary course of our business, including actions arising from tort, contract or other claims. See “Legal Proceedings”
elsewhere in this filing for more information. Litigation is expensive, time consuming, and could divert management’s attention
away from running our business. The outcome of litigation or other proceedings is subject to significant uncertainty, and it is possible
that an adverse resolution of one or more such proceedings could result in reputational harm and/or significant monetary damages, injunctive
relief or settlement costs that could adversely affect our results of operations or financial condition as well as our ability to conduct
our business as it is presently being conducted. Insurance might not cover such claims, might not provide sufficient payments to cover
all the costs to resolve one or more such claims and might not be available on terms acceptable to us. In addition, regardless of merit
or outcome, claims brought against us that are uninsured or underinsured could result in unanticipated costs, which could harm our business,
financial condition and operating results and reduce the trading price of our stock.
For example, we have become aware that we were involved in a transaction
in which an investor of the Company may have resold approximately 175,000 shares of our common stock pursuant to a registration statement
that was not declared effective by the Securities and Exchange Commission (SEC). As a result, it is possible that the SEC brings an action
against us, or we may ultimately be responsible for an action for rescission by purchasers of the securities that were resold. If the
SEC were to bring such an enforcement action against us, or if purchasers were to bring such an action for rescission, it may have a material
adverse effect on our financial position.
16
Product liability lawsuits against us could cause us to incur
substantial liabilities and to limit commercialization of any products that we may develop.
We face an inherent risk of product liability exposure related to the
use of ContraPest and any of our other products. If we cannot successfully defend ourselves against claims from our product users, we
could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in the following:
● decreased demand for any product that we may develop;
● termination of field studies or other research and development efforts;
● injury to our reputation and significant negative media attention;
● significant costs to defend the related litigation;
● substantial monetary awards to plaintiffs;
● loss of revenue;
● the inability to commercialize our product candidates.
We may be unable to obtain commercially reasonable product liability
insurance for any products approved for marketing. Large judgments have been awarded in class action lawsuits based on products that had
unanticipated side effects, including, without limitation, any potential adverse effects of our products on humans or other species. A
successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could
decrease our cash and adversely affect our business.
Risks Related to our Reporting and Cybersecurity
We have not fully assessed our internal control over financial
reporting. If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls,
we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor
confidence in us and, as a result, the value of our Common Stock.
A material weakness is a deficiency, or combination of deficiencies,
in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial
statements will not be prevented or detected on a timely basis.
This Annual Report on Form 10-K for the year ended December 31, 2021
does not include an attestation report of our registered public accounting firm due to a transition period established by rules of the
SEC for smaller reporting companies. As a result, we have not yet fully assessed our internal control over financial reporting and are
unable to assure that the measures we have taken to date, together with any measures we may take in the future, will be sufficient to
remediate the control deficiencies that led to our material weaknesses in our internal control over financial reporting, or to avoid potential
future material weaknesses.
If we are unable to develop and maintain an effective system of internal
control over financial reporting, successfully remediate any existing or future material weaknesses in our internal control over financial
reporting, or identify any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely affected,
we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports and Nasdaq listing
requirements, investors may lose confidence in our financial reporting, and our stock price may decline as a result.
17
Privacy breaches and other cyber security risks related to our
business could negatively affect our reputation, credibility and business.
We are making sales through our new e-Commerce tool, which depends on information
technology systems and networks. We are also responsible for storing data relating to our customers and employees and rely on third party
vendors for the storage, processing and transmission of personal and Company information. Consumers, lawmakers and consumer advocates
alike are increasingly concerned over the security of personal information transmitted over the Internet, consumer identity theft and
privacy. We do not control our third-party service providers and cannot guarantee that they have implemented reasonable security measures
to protect our employees’ and customers’ identity and privacy, or that no electronic or physical computer break-ins or security
breaches will occur in the future. Our systems and technology are vulnerable from time-to-time to damage, disruption or interruption from,
among other things, physical damage, natural disasters, inadequate system capacity, system issues, security breaches, “hackers,”
email blocking lists, computer viruses, power outages and other failures or disruptions outside of our control. A significant breach of
customer, employee or Company data could damage our reputation and our relationship with customers, and could result in lost sales, sizable
fines, significant breach-notification costs and lawsuits, as well as adversely affect our results of operations. We may also incur additional
costs in the future related to the implementation of additional security measures to protect against new or enhanced data security and
privacy threats, or to comply with state, federal and international laws that may be enacted to address those threats.
Risks Related to our Capital Stock, Funding and Trading in our Stock
We have incurred significant operating losses every quarter since
our inception and anticipate that we will continue to incur significant operating losses in the future.
Investment in product development is highly speculative because it
entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to become commercially
viable or gain regulatory approval. To date, we have financed our operations primarily through the sale of equity securities and debt
financings as well as research grants. We have not generated sufficient revenue from product sales to date to achieve profitability .
We continue to incur significant sales, marketing, research, development, and other expenses related to our ongoing operations. As a result,
we are not profitable and have incurred losses in every reporting period since our inception. For the years ended December 31, 2021 and
2020, we reported net losses of $8.3 million and $8.4 million, respectively. As of December 31, 2021, we had an accumulated deficit since
inception of $112.5 million.
Since inception, we have dedicated a majority of our resources to the
discovery and development and marketing of our proprietary product candidates. We expect to continue to incur significant expenses and
operating losses for the foreseeable future. The size of our losses will depend, in part, on the rate of future expenditures and our ability
to generate revenues. In particular, we expect to incur substantial and increased expenses as we perform the following:
● attempt to achieve market acceptance for our products;
● maintain, expand and protect our intellectual property portfolio; and
18
We may encounter unforeseen expenses, difficulties, complications,
delays, and other unknown factors that may adversely affect our financial condition. Our prior losses and expected future losses have
had, and will continue to have, an adverse effect on our financial condition. If ContraPest or any other product candidate does not gain
or maintain sufficient regulatory approval, or if approved, fails to achieve market acceptance, we may never become profitable. Even if
we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become and remain
profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, diversify our product
offerings or continue our operations. A decline in the value of our company could cause you to lose all or part of your investment.
If we are unable to continue as a going concern, our securities
will have little or no value.
We have incurred operating losses since our inception, and we expect
to continue to incur significant expenses and operating losses for the foreseeable future. Our financial statements as of December 31,
2021 and 2020 have been prepared under the assumption that we will continue as a going concern. Our independent registered public accounting
firm included in its opinion for the years ended December 31, 2021 and 2020 an explanatory paragraph referring to our net loss from operations
and net capital deficiency and expressing substantial doubt in our ability to continue as a going concern without additional capital becoming
available. If we encounter continued issues or delays in the commercialization of ContraPest or greater than anticipated expenses, our
prior losses and expected future losses could have an adverse effect on our financial condition and negatively impact our ability to fund
continued operations, obtain additional financing in the future and continue as a going concern. There are no assurances that such financing,
if necessary, will be available to us at all or will be available in sufficient amounts or on reasonable terms. Our financial statements
do not include any adjustments that may result from the outcome of this uncertainty. If we are unable to generate additional funds in
the future through financings, sales of our products, licensing fees, royalty payments or from other sources or transactions, we will
exhaust our resources and will be unable to continue operations. If we cannot continue as a going concern, our stockholders would likely
lose most or all of their investment in us.
Raising additional capital may cause dilution to our existing
stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
Until such time, if ever, as we can generate sufficient product revenues,
we expect to finance our cash needs primarily through the sale of equity securities and debt financings, and possibly through credit facilities
and government and foundation grants. We may also seek to raise capital through third party collaborations, strategic alliances and similar
arrangements. We currently do not have any committed external source of funds.
Raising funds in the future may present additional challenges and future
financing may not be available in sufficient amounts or on terms acceptable to us, if at all. The terms of any financing arrangements
we enter into may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities by us, or
the possibility of such issuance, may cause the market price of our shares to decline. For example, during 2020, we completed equity financings
that resulted in the issuance of shares of Common Stock and warrants to purchase Common Stock, resulting in substantial dilution to the
existing stockholders. Similarly, in the first quarter of 2021, we again issued shares of Common Stock and warrants to purchase Common
Stock, resulting in additional substantial dilution to the existing stockholders. We generally have raised capital as the opportunity
arises.
Certain of our agreements with investors and our outstanding warrants
contain provisions that impose limitations on our ability to participate in certain variable rate transactions, including at-the-market
transactions, which may limit our opportunities to obtain financing in sufficient amounts or on acceptable terms. The sale of additional
equity or convertible debt securities would dilute all of our stockholders, and if such sales occur at a deemed issuance price that is
lower than the current exercise price of our outstanding warrants sold to investors in November 2017, the exercise price for those warrants
would adjust downward to the deemed issuance price pursuant to price adjustment protection contained within those warrants. Our various
warrants contain other terms that may affect our fundraising.
The incurrence of indebtedness through credit facilities would result
in increased fixed payment obligations and, potentially, the imposition of restrictive covenants. Those covenants may include limitations
on our ability to incur additional debt, making capital expenditures or declaring dividends, and may impose limitations on our ability
to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to
conduct our business.
19
If we raise additional funds through collaborations, strategic alliances,
or licensing arrangements or other marketing or distribution arrangements with third parties, we may have to relinquish valuable rights
to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable
to us. If we are unable to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition
and results of operations could be materially adversely affected.
If we are unable to raise additional funds through equity or debt financings
when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts, or grant others
rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
Our share price may be volatile, which could subject us to securities
class action litigation and your investment in our securities could decline in value.
Our stock could be subject to wide fluctuation in response to many
risk factors listed in this section, and others beyond our control, including the following:
● market acceptance and commercialization of our products;
● our ability to remain listed on Nasdaq;
● results and timing of our submissions with the regulatory authorities;
● failure or discontinuation of any of our development programs;
● failure to achieve pricing acceptable to the market;
● regulatory actions with respect to our products or our competitors’ products;
● competition from existing products or new products that may emerge;
● issuance of new or updated research or reports by securities analysts;
● entry by us into any material litigation or other proceedings;
● sales of our Common Stock by us, our insiders, or our other stockholders;
● exercise of outstanding warrants;
● market conditions for equity securities; and
● general economic and market conditions unrelated to our performance.
20
Furthermore,
the capital markets can experience extreme price and volume fluctuations that may affect the market prices of equity securities of many
companies. These broad market and industry fluctuations, as well as general economic, political, and market conditions such as recessions,
interest rate changes, or international currency fluctuations, may negatively impact the market price of shares of our Common Stock.
In addition, such fluctuations could subject us to securities class action litigation, which could result in substantial costs and divert
our management’s attention from other business concerns, which could seriously harm our business. You may not realize any return
on your investment in us and may lose some or all of your investment.
Future
sales, or the possibility of future sales, of a substantial number of our common shares could adversely affect the price of the shares
and dilute stockholders.
Future
sales of a substantial number of shares of our Common Stock, or the perception that such sales will occur, could cause a decline in the
market price of our Common Stock. This is particularly true if we sell our stock at a discount. As of March 29, 2022, we had 121,714
shares of our Common Stock subject to outstanding warrants that contain anti-dilution adjustments that provide for an adjustment to the
exercise price for certain dilutive issuances of securities. If we offer or issue additional securities at a deemed price lower than
the current exercise price of these outstanding warrants, these warrants will adjust pursuant to the price adjustment protection contained
within these warrants. For example, our January 2020 registered direct offering resulted in an additional downward adjustment of the
exercise price of these warrants from $19.00 per share to $7.126 per share and our inducement offering in October 2020 resulted in an
additional downward adjustment of the exercise price of these warrants from $7.126 per share to $1.3659 per share. Any future issuance
of Common Stock or securities convertible or exercisable into our Common Stock could cause a further downward adjustment of the exercise
price of these warrants to the deemed issuance price if the issuance price is less than the exercise price of the warrants at the time
of the new issuance.
Also,
in the future, we may issue additional shares of our Common Stock or other equity or debt securities convertible into Common Stock in
connection with a financing, acquisition, litigation settlement, employee arrangements, or otherwise. Any such issuance could result
in substantial dilution to our existing stockholders and could cause our common share price to decline.
An
active market in the shares may not continue to develop in which investors can resell our Common Stock.
We
cannot predict the extent to which an active market for our Common Stock will continue to develop or be sustained, or how the development
of such a market might affect the market price for our Common Stock. Market conditions in effect at the time you acquire our stock may
not be indicative of the price at which our Common Stock will trade in the future. Investors may not be able to sell their Common Stock
at or above the price they acquired it.
If
securities or industry analysts, or other sources of information, do not publish research, or publish inaccurate or unfavorable
research or other information about our business, our stock price and trading volume could decline.
The
trading market for our Common Stock may depend on the research, reports and other information that securities or industry analysts,
or other third-party sources of information, publish about us or our business. We do not have any control over these analysts or other
third-party sources of information. From time to time inaccurate or unfavorable research or other information about our business,
financial condition, results of operations and stock ownership may be published. We cannot assure that analysts will cover us or
provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our
share price could decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could
lose visibility in the financial markets, which could cause our stock price or trading volume to decline. If incorrect or misleading
information is disseminated publicly by third parties about us, our stock price could decline.
We
may not be able to comply with all applicable listing requirements or standards of The Nasdaq Capital Market and Nasdaq could delist
our Common Stock.
Our Common Stock is listed on The Nasdaq Capital Market. In order to
maintain that listing, we must satisfy minimum financial and other continued listing requirements and standards. On March 2, 2022, we
received a letter from the listing qualifications staff (the “Staff”) of Nasdaq providing notification that the bid price
for our common stock had closed below $1.00 per share for the previous 30 consecutive business days and our common stock no longer meets
the minimum bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A),
we have an initial period of 180 calendar days, or until August 29, 2022, to regain compliance. To regain compliance, the closing bid
price of our common stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before August 29,
2022.
In
the event that we are unable to regain compliance with Rule 5550(a)(2) by August 29, 2022, we may be eligible for an additional 180 calendar
day compliance period. To qualify, we would need to meet the continued listing requirement for market value of publicly held shares and
all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and would
need to provide written notice of our intention to cure the deficiency during the second compliance period, by effecting a reverse stock
split, if necessary. Further, the liquidity of the shares of our Common Stock may be affected adversely by a reverse stock split given
the reduced number of shares that are outstanding following a reverse stock split. In addition, a reverse stock split could increase
the number of stockholders who own odd lots (less than 100 shares) of our Common Stock, creating the potential for such stockholders
to experience an increase in the cost of selling their shares and greater difficulty effecting such sales.
21
In
the event that we remain non-compliant with Rule 5550(a)(2), our Common Stock could be delisted from The Nasdaq Capital Market, which
could have a material adverse effect on our financial condition and which could cause the value of our Common Stock to decline. If our
Common Stock is not eligible for listing or quotation on another market or exchange, trading of our Common Stock could be conducted in
the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC
Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our Common Stock,
and there would likely be a reduction in our coverage by security analysts and the news media, which could cause the price of our Common
Stock to decline further. In addition, it may be difficult for us to raise additional capital if we are not listed on a national securities
exchange.
The
reverse stock split may decrease the liquidity of the shares of our Common Stock.
On February 20, 2020, we implemented a 1-for-20 reverse stock split
of our common stock to regain compliance with the minimum bid price requirement of Nasdaq. The liquidity of the shares of our Common Stock
may be affected adversely by the reverse stock split given the reduced number of shares that are outstanding following the reverse stock
split. In addition, the reverse stock split increased the number of stockholders who own odd lots (less than 100 shares) of our Common
Stock, creating the potential for such stockholders to experience an increase in the cost of selling their shares and greater difficulty
effecting such sales.
Our
corporate documents, Delaware law and certain warrants contain provisions that could discourage, delay or prevent a change in control
of our company.
Provisions
in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger or acquisition involving us that our stockholders
may consider favorable. For example, our certificate of incorporation currently provides for a staggered board of directors, whereby
directors serve for three-year terms, with approximately one-third of the directors coming up for reelection each year. Having a staggered
board will make it more difficult for a third party to obtain control of our board of directors through a proxy contest, which may be
a necessary step in an acquisition of us that is not favored by our board of directors. Additionally, most of our warrants provide a
Black Scholes value-based payment to the warrant holders in connection with certain transactions that may discourage, delay or prevent
a merger or acquisition.
We
are also subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law. Under these provisions,
if anyone becomes an “interested stockholder,” we may not enter into a “business combination” with that person
for three years without special approval, which could discourage a third party from making a takeover offer and could delay or prevent
a change of control. For purposes of Section 203, “interested stockholder” means, generally, someone owning 15% or more
of our outstanding voting stock or an affiliate of ours that owned 15% or more of our outstanding voting stock during the past three
years, subject to certain exceptions as described in Section 203.
Item 1B. Unresolved Staff Comments.
Not
applicable.
Item 2. Properties.
As
of December 31, 2021, our corporate headquarters is located in Phoenix, Arizona, where we lease and occupy approximately 5,529 square
feet of office space pursuant to a lease that commenced on December 1, 2019 and expires on November 30, 2024. Also, as of December 31,
2021, our manufacturing facility occupied a separate facility in Phoenix, Arizona, where we lease and occupy approximately 5,105 square
feet of space. The lease for our manufacturing facility commenced on August 1, 2020 and expires on November 30, 2024. We believe that
our existing facilities are adequate and meet our current needs for business, manufacturing and research.
Item 3. Legal Proceedings.
Information
regarding our legal proceedings is discussed in Note 13 to our financial statements, which is incorporated herein by reference.
Item 4. Mine Safety Disclosures.
Not
applicable.
22
PART
II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Market
Information
Our
common stock is traded on the Nasdaq Capital Market under the symbol “SNES.” Our common stock was initially listed for trading
on the Nasdaq Capital Market on December 8, 2016.
Holders
As
of March 29, 2022, there were approximately 696 holders of record of our common stock. Because many shares of our common stock are held
by brokers and other institutions on behalf of stockholders, we are unable to determine the total number of beneficial owners represented
by these holders of record.
Dividends
We
have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future
earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on
our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of
our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements,
contractual restrictions, business prospects and other factors our board of directors may deem relevant.
Recent
Sales of Unregistered Securities